000296085 001__ 296085
000296085 005__ 20250103121049.0
000296085 0247_ $$2doi$$a10.1016/j.lungcan.2024.108072
000296085 0247_ $$2pmid$$apmid:39740425
000296085 0247_ $$2ISSN$$a0169-5002
000296085 0247_ $$2ISSN$$a1872-8332
000296085 037__ $$aDKFZ-2025-00033
000296085 041__ $$aEnglish
000296085 082__ $$a610
000296085 1001_ $$aAguado-Barrera, Miguel E$$b0
000296085 245__ $$aProfessional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study.
000296085 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2025
000296085 3367_ $$2DRIVER$$aarticle
000296085 3367_ $$2DataCite$$aOutput Types/Journal article
000296085 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1735825548_23499
000296085 3367_ $$2BibTeX$$aARTICLE
000296085 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000296085 3367_ $$00$$2EndNote$$aJournal Article
000296085 520__ $$aWe investigate discrepancies in the assessment of treatment-related symptoms in lung cancer between healthcare professionals and patients, and factors contributing to these discrepancies.Data from 515 participants in the REQUITE study were analysed. Five symptoms (cough, dyspnoea, bronchopulmonary haemorrhage, chest wall pain, dysphagia) were evaluated both before and after radiotherapy. Agreement between healthcare professionals and people with lung cancer was quantified using Gwet's-AC2 coefficient. The influence of clinical variables, comorbidities, and quality-of-life outcomes on agreement was examined through stratified analyses.We found varying levels of agreement between healthcare professionals and people with lung cancer. Bronchopulmonary haemorrhage and dysphagia exhibited very good agreement (meanAC2 > 0.81), while cough and chest wall pain showed substantial agreement (meanAC2 = 0.64 and 0.76, respectively). Dyspnoea had the lowest agreement (meanAC2 = 0.59), with prior chemotherapy significantly reducing agreement levels. Chronic obstructive pulmonary disease (COPD) and early cancer stages also contributed to discrepancies in dyspnoea assessments. Regarding quality-of-life, the most relevant factor was fatigue, which reduced agreement in the assessment of dyspnoea (AC2 = 0.55 vs 0.70), dysphagia (AC2 = 0.48 vs 0.69), cough (AC2 = 0.58 vs 0.82), and chest wall pain (AC2 = 0.77 vs 0.91).Our findings indicate strong alignment between healthcare professionals' and people with lung cancer evaluations of observable treatment-related symptoms, but less consistency for subjective symptoms such as dyspnoea. Factors such as prior chemotherapy, COPD, and cancer stage should be considered when interpreting symptom assessments. Furthermore, our study underscores the importance of integrating quality-of-life considerations, particularly fatigue, into symptom evaluations to mitigate potential biases in symptom perception.
000296085 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000296085 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000296085 650_7 $$2Other$$aCorrelation measures
000296085 650_7 $$2Other$$aFatigue
000296085 650_7 $$2Other$$aLung cancer
000296085 650_7 $$2Other$$aPatient reported outcome measures
000296085 650_7 $$2Other$$aQuality of life
000296085 650_7 $$2Other$$aRadiation effects
000296085 650_7 $$2Other$$aSymptom assessment
000296085 7001_ $$aLopez-Pleguezuelos, Carlos$$b1
000296085 7001_ $$aGómez-Caamaño, Antonio$$b2
000296085 7001_ $$aCalvo-Crespo, Patricia$$b3
000296085 7001_ $$aTaboada-Valladares, Begoña$$b4
000296085 7001_ $$aAzria, David$$b5
000296085 7001_ $$aBoisselier, Pierre$$b6
000296085 7001_ $$aBriers, Erik$$b7
000296085 7001_ $$aChan, Clara$$b8
000296085 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b9$$udkfz
000296085 7001_ $$aCoedo-Costa, Carla$$b10
000296085 7001_ $$aCrujeiras-González, Ana$$b11
000296085 7001_ $$aCuaron, John J$$b12
000296085 7001_ $$aDefraene, Gilles$$b13
000296085 7001_ $$aElliott, Rebecca M$$b14
000296085 7001_ $$aFaivre-Finn, Corinne$$b15
000296085 7001_ $$aFranceschini, Marzia$$b16
000296085 7001_ $$aFuentes-Rios, Olivia$$b17
000296085 7001_ $$aGalego-Carro, Javier$$b18
000296085 7001_ $$aGutiérrez-Enríquez, Sara$$b19
000296085 7001_ $$0P:(DE-He78)dd2a4cfd38fcbd0112e8b6cb387b6753$$aHeumann, Philipp$$b20$$udkfz
000296085 7001_ $$aHigginson, Daniel S$$b21
000296085 7001_ $$aJohnson, Kerstie$$b22
000296085 7001_ $$aLambrecht, Maarten$$b23
000296085 7001_ $$aLang, Philippe$$b24
000296085 7001_ $$aLievens, Yolande$$b25
000296085 7001_ $$aMollà, Meritxell$$b26
000296085 7001_ $$aRamos, Mónica$$b27
000296085 7001_ $$aRancati, Tiziana$$b28
000296085 7001_ $$aRattay, Tim$$b29
000296085 7001_ $$aRimner, Andreas$$b30
000296085 7001_ $$aRosenstein, Barry S$$b31
000296085 7001_ $$aSangalli, Claudia$$b32
000296085 7001_ $$0P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aSeibold, Petra$$b33$$udkfz
000296085 7001_ $$aSperk, Elena$$b34
000296085 7001_ $$aStobart, Hilary$$b35
000296085 7001_ $$aSymonds, Paul$$b36
000296085 7001_ $$aTalbot, Christopher J$$b37
000296085 7001_ $$aVandecasteele, Katrien$$b38
000296085 7001_ $$aVeldeman, Liv$$b39
000296085 7001_ $$aWard, Tim$$b40
000296085 7001_ $$aWebb, Adam$$b41
000296085 7001_ $$aWoolf, David$$b42
000296085 7001_ $$ade Ruysscher, Dirk$$b43
000296085 7001_ $$aWest, Catharine M L$$b44
000296085 7001_ $$aVega, Ana$$b45
000296085 7001_ $$aConsortium, REQUITE$$b46$$eCollaboration Author
000296085 773__ $$0PERI:(DE-600)2025812-4$$a10.1016/j.lungcan.2024.108072$$gVol. 199, p. 108072 -$$p108072$$tLung cancer$$v199$$x0169-5002$$y2025
000296085 909CO $$ooai:inrepo02.dkfz.de:296085$$pVDB
000296085 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000296085 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)dd2a4cfd38fcbd0112e8b6cb387b6753$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000296085 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aDeutsches Krebsforschungszentrum$$b33$$kDKFZ
000296085 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000296085 9141_ $$y2025
000296085 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000296085 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLUNG CANCER : 2022$$d2023-10-24
000296085 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000296085 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000296085 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
000296085 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
000296085 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000296085 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000296085 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000296085 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000296085 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000296085 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bLUNG CANCER : 2022$$d2023-10-24
000296085 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000296085 980__ $$ajournal
000296085 980__ $$aVDB
000296085 980__ $$aI:(DE-He78)C020-20160331
000296085 980__ $$aUNRESTRICTED